 |
14-DAY TRIAL FORMULATIONS MY ACCOUNT |
 | |
| Our Compounding Knowledge, Your Peace of Mind | |
| April 17, 2020 | Volume 17 | Issue 16 | |
| |||||
| |||||
|
Note: With the current situation regarding the global supply of pharmaceuticals, we have been asked to reprint the Editorial of this Newsletter from almost ten years go. As we (the U.S.) are dependent upon other countries for active pharmaceutical ingredients (APIs), we need to be aware of some inherent problems, a few of which are discussed in this newsletter, that are associated with this situation. First, if there is a political disagreement between the countries of the provider and the purchaser, the provider may not be able to "sell" to the "purchaser" for political reasons. This would leave the country purchasing the APIs without the needed medication. Second, there may be a situation when sanctions are placed upon a provider country and the purchaser cannot order and receive the APIs to produce their medications. Third, since many people in some countries receive their health care, including pharmaceuticals, from their government, when the government has severe budget problems and drops the prices they are willing to pay for pharmaceuticals to help balance the budget, the company simply stops selling to the buyer country. This is the case in Greece, where it was reported this past week that the government was not willing to pay the price for insulin that was required by patients with diabetes. It isn't that the company necessarily wants to stop selling to Greece; it is that the lower price the government is willing to pay because of the economic conditions is lower than the price at which the seller is willing to sell for. Consequently, they choose to not sell their product rather than sell at a loss. This may put patients with diabetes that live in Greece in a very dangerous situation. Fourth, quality issues may surface and quality standards may not be met. For example, many providers sell different quality levels of drug substances to different purchasers/countries and the price difference may be such that the seller prefers to sell the lower-quality drug substance at lower prices and may not wish to do the additional work required to produce higher-quality APIs. Fifth, one may not always know the "actual owners" of a company, or they may not always know the actual company that does the synthesis of the APIs since there may be numerous "middle-men" or brokerage firms involved. Sixth, many companies stopped synthesizing APIs here in the U.S. because of the increased OSHA and EPA standards and the fact that it can be done less expensively in other countries with less personnel costs and issues. However, what happens when these countries start increasing their prices and we no longer can source the API from other providers? The U.S. has about 70% to 80% of their APIs synthesized in other countries (primarily China and India), which is potentially a dangerous situation. Maybe it's time that U.S. companies started looking at what it would take to bring this industry back home so that the U.S. manufactures its APIs instead of importing them. Loyd V. Allen, Jr., PhD, RPh Editor-in-Chief IJPC Remington: The Science and Practice of Pharmacy Twenty-second edition | |||||
|
News FDA Releases COVID-19 Compounding Policy
It is avaailable for download at https://www.fda.gov/media/137031/download | |||||
|
Hydroxychloroquine Study Available With the drug "hydroxychloroquine" becoming a familiar word in the COVID-19 battle, please refer to our website to view a stability study titled "Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes." It can be found at: https://ijpc.com/Abstracts/Abstract.cfm?ABS=4322 | |||||
|
Q&A on an Upcoming Article in IJPC "Compounding Pearls - Wound Care: Diabetic Foot Ulcers, Part 1," by Mike Riepl, (May/June 2020 issue of IJPC) Are diabetic foot ulcers classified by type? Which factors cause those ulcers, and why are those lesions so difficult to treat?
Which drugs are effective in healing DFUs?
For an in-depth discussion, effective formulations, and additional information about compounding for the treatment of these DFUs, please see the upcoming May/June 2020 issue of IJPC. | |||||
|
Did You Know ... ...that Will Rogers said the following? "All I know is just what I read in the papers, and that's an alibi for my ignorance." | |||||
|
Tip of the Week We could add all the media (television, radio, social media, etc.) to the newspapers in the above quote. It seems that the media is not as much interested in the "What, When, How, and Where" as they are in the "Why" and the "Gotcha!". And if they don't get the answers they want, they often misrepresent what was said, give their own opinions or only report portions of statements, etc. It also seems that they are now saying their comments have been "Fact-Checked"; however, WHO is checking the "Fact-Checkers?" Even though there are many great, truthful, serious, and honorable journalists, I really don't think journalists will ever be voted as the "most honorable profession" in our lifetimes! | |||||
|
IJPC Now on Facebook and Youtube Become a fan of the IJPC Facebook page and share ideas, photos, and keep up to date with the latest compounding information - https://www.facebook.com/IJPCompounding View our growing collection of educational and training videos at www.ijpc.com/video or by subscribing to our Youtube channel at https://www.youtube.com/IJPCompounding. | |||||
|
Looking Back Tho living costs,
|
| Copyright 2020 IJPC Inc. 122 N Bryant Ave, Edmond OK 73034 |
 |
Manage my Email: Subscribe / Remove from List |
Comments or Questions: info@compoundingtoday.com |
| Reprints & Permissions: Reprints@ijpc.com | |||